CME
Summer
Series

Educational Goal

This educational activity is designed to expand clinicians' proficiency in applying precision oncology principles to the management of solid tumors, including appropriate biomarker testing, interpretation of molecular results, and integration of targeted therapies. Learners will explore how to operationalize precision medicine in both academic and community environments.

A second goal is to improve understanding of emerging therapeutic classes — antibody drug conjugates, bispecifics, next-generation targeted agents — and how to incorporate them into treatment plans while balancing efficacy, safety, and patient-specific factors. Case-based discussions will reinforce practical application.

The final goal is to support clinicians in addressing real-world barriers to precision oncology, including disparities in testing access, clinical trial participation, and navigation of complex care pathways. Learners will leave with actionable strategies to improve equity, communication, and patient engagement.

Learning Objectives

At the end of this activity, participants will be able to:

1. Review updated clinical evidence and guideline recommendations to treatment sequencing and planning.
2. Identify biomarker-driven decision-making into patient management.
3. Identify treatment-related toxicities using current best practices.
4. Explain how to improve multidisciplinary coordination across oncology specialties.
5. Discuss how to address disparities in cancer care affecting hard-to-reach populations.

Target Audience

Medical oncologists, radiation oncologists, surgical oncologists, oncology nurse practitioners, oncology physician assistants, oncology pharmacists, oncology nurses, fellows, residents, and primary care clinicians involved in cancer care.

Primary Agenda

Educational Goal

This activity aims to strengthen clinicians' ability to recognize, diagnose, and manage women's cancers across diverse care settings, with an emphasis on evidence-based screening, risk stratification, and early detection. Faculty will highlight evolving standards of care, disparities in access, and practical strategies for improving patient-centered communication during diagnostic and treatment decision making.

A second goal is to deepen understanding of emerging therapeutic options in breast, gynecologic, and hereditary cancers, including mechanisms of action, biomarker-driven selection, and toxicity management. Learners will gain clarity on how to integrate new data into real-world practice while maintaining safety, equity, and guideline alignment.

Finally, the day aims to equip clinicians with tools to improve coordination across multidisciplinary teams — oncology, primary care, genetics, and supportive services — to reduce delays in care and improve outcomes for women across the cancer continuum.

Learning Objectives

At the end of this activity, participants will be able to:

1. Review updated clinical evidence and guideline recommendations to treatment sequencing and planning.
2. Identify biomarker-driven decision-making into patient management.
3. Identify treatment-related toxicities using current best practices.
4. Explain how to improve multidisciplinary coordination across oncology specialties.
5. Discuss how to address disparities in cancer care affecting hard-to-reach populations.

Target Audience

Medical oncologists, radiation oncologists, surgical oncologists, oncology nurse practitioners, oncology physician assistants, oncology pharmacists, oncology nurses, fellows, residents, and primary care clinicians involved in cancer care.

Primary Agenda

Educational Goal

This activity is designed to enhance clinicians' ability to diagnose and manage hematologic malignancies and rare cancers, with a focus on recognizing atypical presentations, selecting appropriate diagnostic workups, and applying current treatment algorithms. Emphasis will be placed on conditions that disproportionately affect underserved populations or are frequently under-recognized in community settings.

A second goal is to update learners on rapidly evolving therapeutic landscapes — including targeted agents, immunotherapies, and cellular therapies — while clarifying indications, sequencing considerations, and toxicity mitigation. Faculty will translate complex clinical trial data into practical, real-world decision frameworks.

The final goal is to strengthen interdisciplinary collaboration between oncology, hematology, pathology, pharmacy, and supportive care teams to improve care coordination, reduce preventable complications, and optimize patient outcomes in rare and high-risk malignancies.

Learning Objectives

At the end of this activity, participants will be able to:

1. Review updated clinical evidence and guideline recommendations to treatment sequencing and planning.
2. Identify biomarker-driven decision-making into patient management.
3. Identify treatment-related toxicities using current best practices.
4. Explain how to improve multidisciplinary coordination across oncology specialties.
5. Discuss how to address disparities in cancer care affecting hard-to-reach populations.

Target Audience

Medical oncologists, radiation oncologists, surgical oncologists, oncology nurse practitioners, oncology physician assistants, oncology pharmacists, oncology nurses, fellows, residents, and primary care clinicians involved in cancer care.

Primary Agenda